Galit Granot
Tel Aviv, TA, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Glucose-6-phosphate dehydrogenase deficiency is associated with improved survival in patients with acute myeloid leukemia treated with venetoclax and azacitidine.
Journal: Cancer
Published: October 03, 2025
Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors - systematic review and meta-analysis of randomized controlled trials.
Journal: Annals of hematology
Published: May 13, 2025
Interferon-α Inhibits NET Formation in Neutrophils Derived from Patients with Myeloproliferative Neoplasms in a Neutrophil Sub-Population-Specific Manner.
Journal: International journal of molecular sciences
Published: November 05, 2024
Dasatinib induces endothelial dysfunction leading to impaired recovery from ischaemia.
Journal: British journal of haematology
Published: April 08, 2024
Extracorporeal photopheresis induces NETosis in neutrophils derived from patients with chronic graft-vs-host disease.
Journal: Journal of clinical apheresis
Published: November 15, 2022
Using natural killer cell-derived exosomes as a cell-free therapy for leukemia.
Journal: Hematological oncology
Published: September 21, 2022
Neutrophil Extracellular Traps Are Increased in Chronic Myeloid Leukemia and Are Differentially Affected by Tyrosine Kinase Inhibitors.
Journal: Cancers
Published: November 17, 2021
Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species- and GSK3β-dependent mechanism.
Journal: British journal of haematology
Published: July 15, 2020
Profiling and bioinformatics analyses reveal chronic lymphocytic leukemia cells share a unique circular RNA expression pattern.
Journal: Experimental hematology
Published: November 14, 2019
Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
Journal: Leukemia & lymphoma
Published: May 10, 2018
Deferasirox selectively induces cell death in the clinically relevant population of leukemic CD34+CD38- cells through iron chelation, induction of ROS, and inhibition of HIF1α expression.
Journal: Experimental hematology
Published: April 24, 2018
Ponatinib reduces viability, migration, and functionality of human endothelial cells.
Journal: Leukemia & lymphoma
Published: October 14, 2016
Last Updated: 09/26/2026